A noticeable meta-analysis of the anti-inflammatory capacity of melatonin administration has recently confirmed, based on 13 studies and a global cohort of 749 people, the reduction of TNF-α and IL-6 levels [174], suggesting that it would have a similar effect on COVID-19 patients. The gene discussed is TNF; the disease is COVID-19.